Ray Therapeutics

Founded in 2021, Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation. We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision. We are advancing our pipeline of optogenetic medicines to address a range of degenerative retinal diseases, with programs in both preclinical and clinical stages of development. Ray Therapeutics’ lead candidate, RTX-015, is bioengineered to repurpose retinal ganglion cells to restore vision, and is being evaluated in a Phase 1 trial in Retinitis Pigmentosa and Choroideremia.